The product labeling reflects the evidence that sacubitril/valsartan reduces NT-proBNP levels and is expected to improve cardiovascular outcomes in pediatric patients with heart failure with systemic left ventricular systolic dysfunction (48). The gene discussed is NPPB; the disease is heart failure.